Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging System

Journal of the American College of Cardiology

Volumn 68, Issue 10, 2016, Pages 1014-1020

  Grogan, Martha ^a   Scott, Christopher G ^a   Kyle, Robert A ^a   Zeldenrust, Steven R ^a   Gertz, Morie A ^a   Lin, Grace ^a   Klarich, Kyle W ^a   Miller, Wayne L ^a   Maleszewski, Joseph J ^a   Dispenzieri, Angela ^a  

^a MAYO CLINIC   (United States)

Author keywords

amyloidosis; senile systemic amyloidosis; transthyretin; wild type

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; PREALBUMIN; TROPONIN T; BRAIN NATRIURETIC PEPTIDE; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ADULT; AGE; AGED; ARTICLE; DISEASE COURSE; DYSPNEA; ECHOCARDIOGRAPHY; FEMALE; HAZARD RATIO; HEART AMYLOIDOSIS; HEART ATRIUM ARRHYTHMIA; HEART EJECTION FRACTION; HEART FAILURE; HEART MUSCLE BIOPSY; HUMAN; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; MIDDLE AGED; MORTALITY; OVERALL SURVIVAL; PERICARDIAL EFFUSION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; RISK ASSESSMENT; SEX DIFFERENCE; SURVIVAL RATE; SYMPTOM; VERY ELDERLY; WILD TYPE TRANSTHYRETIN CARDIAC AMYLOIDOSIS; AMYLOID NEUROPATHIES, FAMILIAL; BLOOD; COMPLICATION; HEART DISEASES;

AGED; AGED, 80 AND OVER; AMYLOID NEUROPATHIES, FAMILIAL; FEMALE; HEART DISEASES; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL RATE; TROPONIN T;

EID: 84994501751     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2016.06.033     Document Type: Article

References (23)

1. 1 Steiner, I., The first report of “senile” amyloidosis of the heart, I: Soyka, 1876, Prague [in Czech]. Cesk Patol 20 (1984), 11–13.
2. 2 Dahlin, D.C., Edwards, J.E., Amyloid localized in the heart. Proc Staff Meet Mayo Clin 24 (1949), 89–98.
3. 3 Pomerance, A., Senile cardiac amyloidosis. Br Heart J 27 (1965), 711–718.
4. 4 Hodkinson, H.M., Pomerance, A., The clinical significance of senile cardiac amyloidosis: a prospective clinico-pathological study. Q J Med 46 (1977), 381–387.
5. 5 Lie, J.T., Hammond, P.I., Pathology of the senescent heart: anatomic observations on 237 autopsy studies of patients 90 to 105 years old. Mayo Clin Proc 63 (1988), 552–564.
6. 6 Wright, J.R., Calkins, E., Amyloid in the aged heart: frequency and clinical significance. J Am Geriatr Soc 23 (1975), 97–103.
7. 7 Gertz, M.A., Kyle, R.A., Edwards, W.D., Recognition of congestive heart failure due to senile cardiac amyloidosis. Biomed Pharmacother 43 (1989), 101–106.
8. 8 Sletten, K., Westermark, P., Natvig, J.B., Senile cardiac amyloid is related to prealbumin. Scand J Immunol 12 (1980), 503–506.
9. 9 Westermark, P., Sletten, K., Johansson, B., Cornwall, G.G. 3rd, Fibril in senile systemic amyloidosis is derived from normal transthyretin. Proc Natl Acad Sci U S A 87 (1990), 2843–2845.
10. 10 Pitkanen, P., Westermark, P., Cornwell, G.G. 3rd, Senile systemic amyloidosis. Am J Pathol 117 (1984), 391–399.
11. 11 Rapezzi, C., Merlini, G., Quarta, C.C., et al. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation 120 (2009), 1203–1212.
12. 12 Liu, P.P., Smyth, D., Wild-type transthyretin amyloid cardiomyopathy: a missed cause of heart failure with preserved ejection fraction with evolving treatment implications. Circulation 133 (2016), 245–247.
13. 13 Pinney, J.H., Smith, C.J., Taube, J.B., et al. Systemic amyloidosis in England: an epidemiological study. Br J Haematol 161 (2013), 525–532.
14. 14 Connors, L.H., Sam, F., Skinner, M., et al. Heart failure resulting from age-related cardiac amyloid disease associated with wild-type transthyretin: a prospective, observational cohort study. Circulation 133 (2016), 282–290.
15. 15 Falk, R.H., Senile systemic amyloidosis: are regional differences real or do they reflect different diagnostic suspicion and use of techniques?. Amyloid 19:Suppl 1 (2012), 68–70.
16. 16 Mohammed, S.F., Mirzoyev, S.A., Edwards, W.D., et al. Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction. J Am Coll Cardiol HF 2 (2014), 113–122.
17. 17 Gonzalez-Lopez, E., Gallego-Delgado, M., Guzzo-Merello, G., et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J 36 (2015), 2585–2594.
18. 18 Contal, C., O'Quigley, J., An application of changepoint methods in studying the effect of age on survival in breast cancer. Comput Stat Data Anal 30 (1999), 253–270.
19. 19 Olson, L.J., Gertz, M.A., Edwards, W.D., et al. Senile cardiac amyloidosis with myocardial dysfunction: diagnosis by endomyocardial biopsy and immunohistochemistry. N Engl J Med 317 (1987), 738–742.
20. 20 Dispenzieri, A., Gertz, M.A., Kyle, R.A., et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol 22 (2004), 3751–3757.
21. 21 Dispenzieri, A., Gertz, M.A., Kyle, R.A., et al. Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 104 (2004), 1881–1887.
22. 22 Kumar, S., Dispenzieri, A., Lacy, M.Q., et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol 30 (2012), 989–995.
23. 23 Palladini, G., Barassi, A., Klersy, C., et al. The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis. Blood 116 (2010), 3426–3430.